Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression

Bork, E., Ersbøll, J., Dombernowsky, P., Bergman, B., Hansen, M. & Hansen, H. H. (1991). Teniposide and etoposide in previously untreated small-cell lung cancer: a randomised study. J Clin Oncol 9: 1627–1631.

Bork, E., Hirsch, F. R., Jeppesen, N., Lassen, U., Vallentin, S., Østerlind, K., Mejer, J., Ingeberg, S., Bergman, B. & Dombernowsky, P. (1997). Oral etoposide (VP-16) every 3 wks. or continuously to elderly patients with small cell lung cancer (SCLC). Preliminary results of a randomaized study. Lung Cancer 18: (suppl.1) 25

Fetscher, M., Brugger, W., Engelhardt, R., Kanz, L., Hasse, J., Frommhold, H., Wenger, M., Lange, W. & Mertelsmann, R. (1997). Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer. Ann Oncol 8: 49–56.

Girling, D. J., Hopwood, P., Lallemand, G., Machin, D., Stephens, R. J. & Baily, A. J. (1996a). Randomised trial of four-drug vs. less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Br J Cancer 73: 406–413.

Girling, D., Thatcher, N., Clark, P. I., Hopwood, P., Twiddy, S. & Stephens, R. J. (1996b). Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Group. Lancet 31: 563–566.

Hirsch, F. R., Hansen, H. H., Hansen, M., Østerlind, K., Vindeløv, L. L., Dombernowsky, P. & Sörensson, S. (1987). The superiority of combination chemotherapy including etoposide based on in vivo small-cell lung cancer: a randomized trial of 288 consecutive patients. J Clin Oncol 5: 585–591.

Jackson, D. V., Case, L. D., Zekan, P. J., Powell, B. L., Caldwell, R. D., Bearden, J. D., Nelson, E. C., Muss, A. B., Cooper, M. R., Richard, SIIF, White, D. R., Cruz, J. M., Caponera, M. E., Furr, C. S., Spurr, C. L. & Capizzi, R. L. (1988). Improvement of long-term survival in extensive small-cell lung cancer. J Clin Oncol 6: 1161–1169.

Johnson, D. H., Einhorn, L. H., Birch, R., Vollmer, R., Perez, C., Krauss, S., Omura, G. & Greco, A. (1987). A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 5: 1731–1738.

Kalwinsky, D. K., Look, A. T., Ducore, J. & Fridland, A. L. (1983). Effects of the epipodophyllotoxin VP-16-213 on the cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts. Cancer Res 43: 1592–1597.

Katakami, N., Takada, M., Negore, S., Ota, K., Fujita, J., Aryoshi, Y., Ikegami, H. & Fukuoka, M. (1996). Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. Cancer 77: 63–70.

Klasa, R. J., Murray, N. & Coldman, A. J. (1991). Dose-intensity meta-analysis of chemotherapy regiments in small-cell carcinoma of the lung. J Clin Oncol 9: 499–508.

Kristjansen, P. E. G. & Hansen, H. H. (1990). Management of small cell lung cancer: a summary of the third International Association for the Study of Lung Cancer Workshop on Small Cell Lung Cancer. J Natl Cancer Inst 82: 263–266.

Lassen, U., Kristjansen, P. E. G., Østerlind, K., Bergman, B., Sigsgaard, T. C., Hirsch, F. R., Hansen, M., Dombernowsky, P. & Hansen, H. H. (1996). Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann Oncol 7: 365–371.

Lassen, U., Hirsch, F. R., Østerlind, K., Bergman, B., Dombernowsky, P. & Hansen, H. H. (1998). Outcome of combination chemotherapy in extensive stage small cell lung cancer. Any treatment related progress? Lung Cancer 20: 151–160.

Morittu, L., Earl, H. M., Souhami, R. L., Ash, C. M., Tobias, J. C., Geddes, D. M., Harper, P. G. & Spiro, S. G. (1989). Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. Br J Cancer 59: 801–804.

Murray, N., Livingston, R. B., Shephard, F. A., James, K., Zee, B. C., Langle-Ben, A., Kraut, M., Bearden, J., Goodwin, J., Crafton, C., Turrisi, A. T., Walde, D., Croft, H. & Ottaway, J. (1997). A randomized study of CODE plus thoracic irradiation versus alternating CAV/EP for extensive stage small cell lung cancer (ESCLC). Proc Am Soc Clin Oncol 16: 456

Østerlind, K., Sörensson, S., Hansen, H. H., Dombernowsky, P., Hirsch, F. R., Hansen, M. & Rørth, M. (1983). Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res 43: 6085–6089.

Østerlind, K., Hansen, H. H., Hansen, H. S., Dombernowsky, P., Hansen, M. & Rørth, M. (1986). Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up. Br J Cancer 54: 7–17.

Østerlind, K., Hansen, M., Hirsch, F. R., Dombernowsky, P., Sörensson, S., Pedersen, A. G. & Hansen, H. H. (1991). Combination chemotherapy of limited small cell lung cancer. A controlled trial on 222 patients comparing two alternating regimens. Ann Oncol 2: 41–46.

Pedersen, A. G., Østerlind, K., Vindeløv, L., Sörensson, S., Hansen, M., Dombernowsky, P. & Hansen, H. H. (1987). Alternating or continuous chemotherapy of small cell lung cancer. A three armed randomized trial (abstract). Proc Am Soc Clin Oncol 6: 187

Pfluger, K-H, Schmidt, L., Merkel, M., Jungclas, H. & Havemann, K. (1987). Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide. Cancer Chemother Pharmacol 20: 59

Radford, J. A., Ryder, W. D. J., Dodwell, D., Anderson, H. & Thatcher, N. (1993). Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer 29A: 81–86.

Souhami, R. L., Spiro, S. G., Rudd, R. M., Ruiz De Elvera, M. C., James, L. E., Gower, N. H., Lamont, A. & Harper, P. G. (1997). Five-day oral etoposide treatment for advanced small-cell lung cancer. Randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 89: 577–580.

SPSS for Windows Statistical package, version 6.1.3, (1995).

Stahel, R. A., Takvorian, R. W., Skarin, A. T. & Canellos, G. P. (1984). Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU, and VP-16 in small cell carcinoma of the lung and a review of the literature. Eur J Cancer Clin Oncol 20: 1233–1238.

Stephens, R. J., Girling, D. J. & Machin, D. (1994). Treatment related deaths in small cell lung cancer trials: can patients at risk be identified?. Lung Cancer 11: 259–274.